2-({6-[3-chloro-4-(trifluoromethyl)phenyl]pyrimidin-4-yl}amino)-1-[3-fluorophenyl]ethanol | 1184848-90-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 2-({6-[3-chloro-4-(trifluoromethyl)phenyl]pyrimidin-4-yl}amino)-1-[3-fluorophenyl]ethanol
• 英文别名: 2-[[6-[3-Chloro-4-(trifluoromethyl)phenyl]pyrimidin-4-yl]amino]-1-(3-fluorophenyl)ethanol
• CAS: 1184848-90-5
• 化学式: C₁₉H₁₄ClF₄N₃O
• 分子量: 411.786
• InChiKey: HVNPAPLTAKSZEE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  28
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.16
• 拓扑面积：
  58
• 氢给体数：
  2
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  2-(3-fluorophenyl)-2-((trimethylsilyl)oxy)acetonitrile 在 lithium aluminium tetrahydride 、 碳酸氢钠 作用下， 以 四氢呋喃 、 1,4-二氧六环 为溶剂， 生成 2-({6-[3-chloro-4-(trifluoromethyl)phenyl]pyrimidin-4-yl}amino)-1-[3-fluorophenyl]ethanol
  参考文献：
  名称：

  1-Aryl-2-((6-aryl)pyrimidin-4-yl)amino)ethanols as competitive inhibitors of fatty acid amide hydrolase

  摘要：

  A series of 1-aryl-2-(((6-aryl)pyrimidin-4-yl)amino)ethanols have been found to be competitive inhibitors of fatty acid amide hydrolase (FAAH). One member of this class, JNJ-40413269, was found to have excellent pharmacokinetic properties, demonstrated robust central target engagement, and was efficacious in a rat model of neuropathic pain. (C) 2014 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2014.01.064

文献信息

• [EN] ARYL-HYDROXYETHYLAMINO-PYRIMIDINES AND TRIAZINES AS MODULATORS OF FATTY ACID AMIDE HYDROLASE<br/>[FR] ARYL-HYDROXYÉTHYLAMINO-PYRIMIDINES ET TRIAZINES EN TANT QUE MODULATEURS D'AMIDE D'ACIDE GRAS HYDROLASE
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2009105220A1

  公开（公告）日：2009-08-27

  Certain aryl-hydroxyethylamino-pyrimidine and triazine compounds are described, which are useful as FAAH inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolase (FAAH) activity, such as anxiety, pain, inflammation, sleep disorders, eating disorders, energy metabolism disorders, and movement disorders (e.g., multiple sclerosis). Methods of synthesizing such compounds are also disclosed.

  描述了某些芳基-羟乙基氨基嘧啶和三嗪化合物，这些化合物可用作FAAH抑制剂。这些化合物可用于制备药物组合物和治疗由脂肪酸酰胺水解酶（FAAH）活性介导的疾病状态、紊乱和症状，如焦虑、疼痛、炎症、睡眠障碍、进食障碍、能量代谢障碍和运动障碍（例如多发性硬化）。还公开了合成这些化合物的方法。
• Aryl - Hydroxyethylamino - Pyrimidines and Triazines as Modulators of Fatty Acid amide Hydrolase
  申请人：Apodaca Richard

  公开号：US20090264429A1

  公开（公告）日：2009-10-22

  Certain aryl-hydroxyethylamino-pyrimidine and triazine compounds are described, which are useful as FAAH inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolase (FAAH) activity, such as anxiety, pain, inflammation, sleep disorders, eating disorders, energy metabolism disorders, and movement disorders (e.g., multiple sclerosis). Methods of synthesizing such compounds are also disclosed.

  描述了某些芳基-羟乙基氨基嘧啶和三嗪化合物，这些化合物可用作FAAH抑制剂。这些化合物可以用于制备药物组合物和治疗由脂肪酸酰胺水解酶（FAAH）活性介导的疾病状态、障碍和病况的方法，例如焦虑、疼痛、炎症、睡眠障碍、进食障碍、能量代谢障碍和运动障碍（例如多发性硬化症）。还公开了合成这些化合物的方法。
• ARYL-HYDROXYETHYLAMINO-PYRIMIDINES AND TRIAZINES AS MODULATORS OF FATTY ACID AMIDE HYDROLASE
  申请人：Janssen Pharmaceutica, N.V.

  公开号：EP2254415A1

  公开（公告）日：2010-12-01
• US8598202B2
  申请人：——

  公开号：US8598202B2

  公开（公告）日：2013-12-03
• 1-Aryl-2-((6-aryl)pyrimidin-4-yl)amino)ethanols as competitive inhibitors of fatty acid amide hydrolase
  作者：John M. Keith、Natalie Hawryluk、Richard L. Apodaca、Allison Chambers、Joan M. Pierce、Mark Seierstad、James A. Palmer、Michael Webb、Mark J. Karbarz、Brian P. Scott、Sandy J. Wilson、Lin Luo、Michelle L. Wennerholm、Leon Chang、Michele Rizzolio、Sandra R. Chaplan、J. Guy Breitenbucher

  DOI：10.1016/j.bmcl.2014.01.064

  日期：2014.3

  A series of 1-aryl-2-(((6-aryl)pyrimidin-4-yl)amino)ethanols have been found to be competitive inhibitors of fatty acid amide hydrolase (FAAH). One member of this class, JNJ-40413269, was found to have excellent pharmacokinetic properties, demonstrated robust central target engagement, and was efficacious in a rat model of neuropathic pain. (C) 2014 Elsevier Ltd. All rights reserved.